Medicenna Therapeutics (TSE:MDNA) Sets New 52-Week Low – Should You Sell?

Medicenna Therapeutics Corp. (TSE:MDNA)’s share price hit a new 52-week low during trading on Tuesday . The company traded as low as C$0.42 and last traded at C$0.41, with a volume of 87461 shares trading hands. The stock had previously closed at C$0.42.

Medicenna Therapeutics Stock Performance

The company has a quick ratio of 4.65, a current ratio of 2.68 and a debt-to-equity ratio of 3.30. The company has a market cap of C$34.20 million, a P/E ratio of -2.73 and a beta of 2.89. The business has a fifty day moving average of C$0.54 and a 200 day moving average of C$0.81.

Medicenna Therapeutics (TSE:MDNA) last announced its earnings results on Thursday, April 30th. The company reported C($0.06) EPS for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%. On average, equities analysts predict that Medicenna Therapeutics Corp. will post -0.37 EPS for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.